AstraZeneca PLC

OTCPK:AZNC.F Stock Report

Market Cap: US$284.1b

AstraZeneca Valuation

Is AZNC.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of AZNC.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: AZNC.F ($182.68) is trading below our estimate of fair value ($330.69)

Significantly Below Fair Value: AZNC.F is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for AZNC.F?

Key metric: As AZNC.F is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for AZNC.F. This is calculated by dividing AZNC.F's market cap by their current earnings.
What is AZNC.F's PE Ratio?
PE Ratio30.2x
EarningsUS$9.40b
Market CapUS$284.08b

Price to Earnings Ratio vs Peers

How does AZNC.F's PE Ratio compare to its peers?

The above table shows the PE ratio for AZNC.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average16.6x
MRK Merck
13.9x6.49%US$261.3b
JNJ Johnson & Johnson
19.8x2.00%US$498.6b
BMY Bristol-Myers Squibb
18x1.01%US$109.8b
PFE Pfizer
14.5x-0.11%US$141.6b
AZNC.F AstraZeneca
30.2x12.51%US$210.8b

Price-To-Earnings vs Peers: AZNC.F is expensive based on its Price-To-Earnings Ratio (30.2x) compared to the peer average (16.6x).

Price to Earnings Ratio vs Industry

How does AZNC.F's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

8 CompaniesPrice / EarningsEstimated GrowthMarket Cap
OGN Organon
3.8x19.13%US$1.86b
NDOI Endo
0.3xn/aUS$1.76b
BTMD biote
2.9x-52.22%US$118.72m
ORMP Oramed Pharmaceuticals
2.6xn/aUS$113.44m
AZNC.F 30.2xIndustry Avg. 19.8xNo. of Companies8PE01632486480+
8 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: AZNC.F is expensive based on its Price-To-Earnings Ratio (30.2x) compared to the US Pharmaceuticals industry average (19.8x).

Price to Earnings Ratio vs Fair Ratio

What is AZNC.F's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

AZNC.F PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio30.2x
Fair PE Ratio32.9x

Price-To-Earnings vs Fair Ratio: AZNC.F is good value based on its Price-To-Earnings Ratio (30.2x) compared to the estimated Fair Price-To-Earnings Ratio (32.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst AZNC.F forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$182.68
US$201.51
+10.31%
12.09%US$245.47US$137.86n/a19
Dec ’26US$180.35
US$193.51
+7.30%
11.68%US$242.15US$137.86n/a19
Nov ’26US$163.68
US$191.70
+17.12%
11.10%US$238.96US$141.01n/a19
Oct ’26US$162.56
US$185.65
+14.21%
13.69%US$243.87US$145.39n/a19
Sep ’26US$161.13
US$183.39
+13.81%
13.71%US$243.87US$145.39n/a19
Aug ’26US$147.50
US$181.87
+23.30%
12.33%US$233.13US$145.39n/a19
Jul ’26US$139.71
US$182.84
+30.87%
12.82%US$231.23US$146.18n/a20
Jun ’26US$141.50
US$181.80
+28.48%
12.41%US$231.23US$146.10n/a20
May ’26US$140.63
US$181.97
+29.39%
12.83%US$231.23US$146.10n/a20
Apr ’26US$148.12
US$181.36
+22.44%
13.50%US$246.74US$135.63n/a20
Mar ’26US$150.46
US$177.44
+17.93%
13.20%US$240.45US$135.63n/a20
Feb ’26US$140.72
US$172.72
+22.74%
13.61%US$222.30US$128.01n/a19
Jan ’26US$130.00
US$177.01
+36.17%
13.44%US$227.61US$133.86US$175.5019
Dec ’25US$136.50
US$177.65
+30.14%
13.26%US$228.68US$133.86US$180.3519
Nov ’25US$142.85
US$185.21
+29.65%
15.28%US$260.47US$137.39US$163.6819
Oct ’25US$155.52
US$185.25
+19.12%
14.58%US$260.47US$139.36US$162.5620
Sep ’25US$175.00
US$180.63
+3.22%
11.73%US$225.81US$141.40US$161.1321
Aug ’25US$160.60
US$180.21
+12.21%
11.56%US$225.81US$141.40US$147.5022
Jul ’25US$157.50
US$174.63
+10.88%
12.07%US$225.81US$137.44US$139.7122
Jun ’25US$153.78
US$172.28
+12.03%
12.27%US$225.07US$137.44US$141.5022
May ’25US$151.02
US$164.80
+9.12%
13.46%US$220.19US$131.28US$140.6320
Apr ’25US$135.80
US$161.21
+18.71%
14.93%US$222.17US$119.95US$148.1221
Mar ’25US$130.00
US$162.01
+24.62%
14.27%US$224.59US$120.02US$150.4621
Feb ’25US$132.12
US$164.67
+24.63%
12.06%US$217.13US$136.17US$140.7221
Jan ’25US$134.45
US$165.29
+22.94%
10.40%US$212.35US$134.25US$130.0021
US$201.16
Fair Value
9.2% undervalued intrinsic discount
19
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/01/02 22:45
End of Day Share Price 2026/01/02 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

AstraZeneca PLC is covered by 62 analysts. 22 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullABG Sundal Collier
John EadeArgus Research Company
Odile RundquistBaader Helvea Equity Research